PTCT
PTC TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The post-earnings bull case is that Sephience launch momentum is proving stronger and broader than expected, the Q1 beat justified a guidance raise, and votoplam plus the disclosed $50M Novartis milestone add pipeline-backed cash support. PTCT also traded materially above the 2026-05-07 anchor after the release, consistent with a favorable initial market read.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Emflaza revenue fell year over year due to continued generic erosion, offsetting part of the broader portfolio strength.
Momentum
44
Value
59
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $82.00 · Bear $54.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $96.07
Why
Momentum44 · Δ7d +8.9
Value59 · Δ7d -0.1
Sentiment37 · Δ7d -1.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
44
26% active weight
Current posture
7d trendSoftening
Δ7d
+8.9
Δ21d
-12.7
Value
59
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
37
34% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
+1.5
Why this grade
Composite grade D. Momentum 44.3 / Value 59.1 / Sentiment 36.7
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$6.5B
Beta
0.48
Shares Out
82.95M
P/E (TTM)
9.0
P/S (TTM)
3.46
P/FCF (TTM)
8.74
Rev YoY
-76.8%
EPS YoY
-100.3%
Gross Margin
+88.5%
Op Margin
+49.2%
Net Debt
-$1.55B
Current Ratio
2.44
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology